AbbVie (ABBV) Accounts Payables (2012 - 2026)

AbbVie (ABBV) has 15 years of Accounts Payables data on file, last reported at $33.8 billion in Q1 2026.

• Accounts Payables for Q1 2026 came in at $33.8 billion, up 8.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.8 billion (up 8.8% YoY), and the FY2025 annual result was $34.7 billion, up 8.73% from the prior year.
• Accounts Payables eased to $33.8 billion in Q1 2026 per ABBV's latest filing, from $34.7 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $34.7 billion in Q4 2025 and troughed at $22.5 billion in Q2 2022.
• A 5-year average of $29.1 billion and a median of $30.5 billion in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables gained 26.37% in 2024, then decreased 0.91% in 2025.
• A 5-year view of Accounts Payables shows it stood at $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then advanced by 8.73% to $34.7 billion in 2025, then retreated by 2.76% to $33.8 billion in 2026.
• Business Quant data shows ABBV's Accounts Payables at $33.8 billion in Q1 2026, $34.7 billion in Q4 2025, and $33.6 billion in Q3 2025.